About Technology Issues FAQ

Links

1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)

1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC) — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.